Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark.
| Revenue (Most Recent Fiscal Year) | $3.12B |
| Net Income (Most Recent Fiscal Year) | $1.14B |
| PE Ratio (Current Year Earnings Estimate) | 14.25 |
| PE Ratio (Trailing 12 Months) | 14.88 |
| PEG Ratio (Long Term Growth Estimate) | 6.82 |
| Price to Sales Ratio (Trailing 12 Months) | 4.10 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.50 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 13.64 |
| Pre-Tax Margin (Trailing 12 Months) | 40.96% |
| Net Margin (Trailing 12 Months) | 35.11% |
| Return on Equity (Trailing 12 Months) | 18.08% |
| Return on Assets (Trailing 12 Months) | 14.52% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.34 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.32 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 17.23 |
| Book Value per Share (Most Recent Fiscal Quarter) | $8.04 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.31 |
| Earnings per Share (Most Recent Fiscal Year) | $1.46 |
| Diluted Earnings per Share (Trailing 12 Months) | $1.76 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 641.22M |
| Free Float | 631.35M |
| Market Capitalization | $13.26B |
| Average Volume (Last 20 Days) | 1.31M |
| Beta (Past 60 Months) | 0.96 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.54% |
| Percentage Held By Institutions (Latest 13F Reports) | 7.07% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |